Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Michael R. Migden"'
Autor:
Ruth Plummer, Ralf Gutzmer, Anne Lynn S. Chang, John T. Lear, Martin Kaatz, Uwe Trefzer, Alexandros Stratigos, Carmen Loquai, Luc Dirix, Patrick Combemale, Nicholas Squittieri, Karl D. Lewis, Reinhard Dummer, Michael R. Migden, A Guminksi, Ragini R. Kudchadkar, H.-J. Schulze
Publikováno v:
British Journal of Dermatology. 182:1369-1378
Background: Basal cell carcinomas (BCCs) exhibit aberrant activation of the hedgehog pathway. Sonidegib is a hedgehog pathway inhibitor approved for the treatment of locally advanced BCC (laBCC) and metastatic BCC (mBCC) based on primary results of t
Autor:
Reinhard Dummer, Michael R. Migden, Alexander Guminski, Nicholas Squittieri, John T. Lear, Liang Joo Leow
Publikováno v:
Journal of the American Academy of Dermatology. 84(4)
Publikováno v:
Future oncology (London, England). 15(27)
Advanced cutaneous squamous cell carcinoma (cSCC) accounts for only 5% of all cases of cSCC but up to 60% of disease related deaths. Historically, this disease has lacked effective treatment options due to a combination of poor response rate, poor re
Autor:
Alan L. Ho, Johanna C. Bendell, Daniel D. Von Hoff, Ragini R. Kudchadkar, Valerie Andre, Ramon V. Tiu, Les H. Brail, Jeffrey R. Infante, Trevor Tucker, Celine Pitou, Michael R. Migden
Publikováno v:
Clinical Cancer Research. 24:2082-2091
Purpose: The purpose of this study was to determine a recommended phase II dose and schedule of LY2940680 (taladegib) for safe administration to patients with locally advanced/metastatic cancer. Experimental Design: This was a phase I, multicenter, o
Autor:
Aleksandar Sekulic, Michael R. Migden, Nicole Basset-Seguin, Claus Garbe, Anja Gesierich, Christopher D. Lao, Chris Miller, Laurent Mortier, Dedee F. Murrell, Omid Hamid, Jorge F. Quevedo, Jeannie Hou, Edward McKenna, Natalie Dimier, Sarah Williams, Dirk Schadendorf, Axel Hauschild, for the ERIVANCE BCC Investigators
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)
BMC Cancer
BMC Cancer
In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration–approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and 43% in metastatic b
Autor:
Anne Lynn S. Chang, Sarah T. Arron, Michael R. Migden, James A. Solomon, Karl D. Lewis, Simon Yoo, Edward McKenna, Aleksandar Sekulic, Bann Mo Day
Publikováno v:
Oncotarget, vol 7, iss 46
Oncotarget
Oncotarget
Because many patients with unresectable basal cell carcinoma (BCC) are aged ≥65 years, this study explores the efficacy and safety of vismodegib in these patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC) in the ERIVAN
Publikováno v:
Future Oncology. 12:2095-2105
The Hedgehog inhibitors are promising alternative for patients with advanced basal cell carcinoma that are not amenable to radiotherapy or surgery. Sonidegib, also known as LDE225, is an orally available SMO antagonist that was recently approved by t
Autor:
Matthew G. Fury, Kosalai Kal Mohan, Jade Homsi, Irene Brana, Anne Lynn S. Chang, Dirk Schadendorf, Jiaxin Niu, Leonel Hernandez-Aya, Jingjin Li, Alexander Guminski, Badri Modi, Israel Lowy, Jocelyn Booth, Victor Moreno, Melissa Lynne Johnson, Elizabeth Stankevich, Christine H. Chung, Kyriakos P. Papadopoulos, Hani M. Babiker, Michael R. Migden, Brett G.M. Hughes, Lara Dunn, Danny Rischin, Taofeek K. Owonikoko, Alesha A. Thai, Melissa Mathias, George D. Yancopoulos, Frank Seebach, Karl D. Lewis, Annette M. Lim, Guilherme Rabinowits, Marta Gil-Martin, Nikhil I. Khushalani, Axel Hauschild, Bo Gao, Chrysalyne D. Schmults, Siyu Li
Publikováno v:
The New England journal of medicine. 379(4)
Background No systemic therapies have been approved for the treatment of advanced cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy, because the mutation burden of the tumor is high and the disease risk is strongly as
Autor:
Ruth Plummer, Martin Kaatz, Alexander Guminski, Patrick Combemale, Karl D. Lewis, Ragini R. Kudchadkar, Manisha Mone, Dalila Sellami, Jocelyn Zhou, Carmen Loquai, Luc Dirix, Anne Lynn S. Chang, Ralf Gutzmer, John T. Lear, Tingting Yi, Michael R. Migden, Reinhard Dummer, Alexandros Stratigos, Uwe Trefzer, Henry Castro
Publikováno v:
Journal of the European Academy of Dermatology and Venereology
Background Patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC), two difficult-to-treat populations, have had limited treatment options. Sonidegib, a hedgehog pathway inhibitor (HPI), was approved in laBCC based on res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2c71a42ca781cb5725f0ad8c828de1c
https://www.zora.uzh.ch/id/eprint/143585/
https://www.zora.uzh.ch/id/eprint/143585/
Publikováno v:
Future oncology (London, England). 14(6)
Sonidegib, a hedgehog pathway inhibitor, was approved by the US FDA for the treatment of locally advanced basal cell carcinoma which cannot be readily treated with surgery or radiotherapy. The pharmacology and pharmacokinetics of sonidegib will be di